Non-Profit Oversight Entity

Professional oversight
for direct life sciences
investment.

Early-stage life sciences have historically delivered some of the strongest returns in private markets — yet most family offices have never been able to invest directly. Steward is the oversight layer that was missing — giving family offices everything they need to invest directly in early-stage life sciences companies — biotech, healthcare, and medical device — with full accountability built in.

25–39%
for example
estimated annual IRR from expertly managed early-stage biotech funds — the benchmark for life sciences direct investment
GoingPublic.de · Bioscience Valuation ↗
10-year horizon · 91 funds · 2013–2022
Past performance does not guarantee future results.
▶  Watch How It Works How It Works for Investors Apply as a Company →
~$2M
Portfolio commitment
~15
Companies per portfolio
~2yr
Deployment window
10yr
Investment horizon
The Problem

The smarter path to early-stage life sciences
has always been diversification.

Concentrating ~$2M into a single early-stage company is a high-stakes bet. Spreading that same ~$2M across 15 carefully selected companies — at $50K–$250K each — changes the math entirely. You only need one or two to succeed for the portfolio to perform exceptionally. The model has always made sense. What was missing was the infrastructure to make it manageable.

The investment logic

Concentrated approach
~$2M
into a single company
Binary outcome — one bet, all capital at risk
High concentration risk
vs
The Steward approach
~$50K–$250K
× ~15 companies = ~$2M deployed
Only 1–2 breakouts needed to drive exceptional returns
Diversified · Managed risk

The two amber-highlighted positions above illustrate the thesis: across a portfolio of ~15, even a modest hit rate delivers outsized aggregate returns ** over a 2-year deployment horizon — with each position sized between $50K and $250K at your discretion.

Without oversight

Investing without infrastructure

No consolidated view across portfolio companies
Capital released with minimal accountability
Financial review handled ad hoc — or not at all
No structured budget oversight or milestone tracking
Money managers overwhelmed by 15 private positions across varying commitment sizes
The Steward model

Structured oversight at every stage

Unified view — all ~15 companies in one consolidated report
Escrow holds capital until funding goals are met
Semi-annual internal financial review and quarterly milestone check-ins
Ongoing budget oversight and milestone accountability
Flat fee model — covered by portfolio companies after commitment

Why hasn't this existed until now

01
No reporting standard
Private early-stage holdings have never had a consolidated internal review framework
02
Oversight burden
Managing 15 companies individually is operationally prohibitive without dedicated infrastructure
03
No escrow mechanism
Capital has historically flowed without the structured release controls investors need
04
Cost of oversight
Professional oversight was too expensive — until a shared fee model across companies made it viable
How It Works

One process. Three perspectives.

Every party in the Steward model moves through the same structured process — but each experiences it differently. Select your perspective below to see how the workflow unfolds from your vantage point.

1
The Investment Case in Biotech

Turning ~$2M into $28M through
strategic biotech diversification.

The math behind this model is compelling — and it's grounded in how early-stage biotech actually works. Distributed across ~15 carefully selected companies, a ~$2M commitment can generate projected returns of $28M over a 10-year horizon, even with a 60% failure rate built in. Adjust the variables below to explore the portfolio outcomes.

70%
of FDA-approved drugs originate from external sources — not Big Pharma's own R&D pipelines
Source: Syneos Health
25–39%
estimated annual IRR from expertly managed biotech syndicates over a 10-year horizon
Source: Going Public
61%
reduction in VC investment in pre-clinical biotech from 2021 peak — entry window remains well below historic highs
Source: Novotech Whitepaper

Portfolio simulator

Investment per company~$50K–$250K
Approximate direct commitment per portfolio company — no fund fees
Number of companies15
Portfolio size over a 2-year deployment window
Failure rate60%
Industry-standard anticipated failure rate — the majority of early-stage companies will not succeed
Top performer return100×
Upside multiple on a breakout company at exit

Projected portfolio outcome

$28.0M
Projected total portfolio return — 10-year horizon
~$2.0M
Total capital deployed
14×
Gross portfolio multiple
8
Companies that survive
12
Companies that fail

Return model: 1 top performer at selected multiple, 2 breakouts at 10×, remaining survivors at 3× average. Failed positions return $0. Oversight through Steward is what makes this model viable at scale.

Portfolio outcome visualisation — based on current settings

Top performer (100×+)
Breakout (10×)
Modest exit (3×)
Failed position

The VC pullback — your entry window

Pre-clinical biotech VC investment collapsed from $9B in 2021 to $3.5B in 2023 — a 61% reduction. A modest recovery began in 2024 driven by interest rate cuts, but 2025 brought renewed headwinds from tariffs, NIH funding cuts, and FDA uncertainty. Investment remains well below the 2021 peak, keeping valuations favorable and competition limited for patient, direct investors.

Sources: Novotech Whitepaper · EY · GlobalData · HSBC Innovation Banking
* 2024–2025 are broader biotech VC estimates; pre-clinical subset pending updated sourcing
2021
$9.0B
2022
$6.5B
2023
$3.5B
2024
~$4.5B*
2025
~$4.0B*
Now
Window

* Projected returns are illustrative and based on industry research. They rely on proper portfolio capitalization, expert scientific evaluation, IP assessment, and structured financial oversight — which is precisely what the Steward model is designed to provide. Past performance of comparable portfolios does not guarantee future results. These figures should not be construed as investment advice. The majority of early-stage companies will not succeed. 2024–2025 VC figures are broader biotech estimates. Sources: Going Public, Novotech Whitepaper, Syneos Health, BioWorld, EY, GlobalData, HSBC Innovation Banking.

Oversight Services

Everything a family office needs.
Nothing they have to manage.

Steward provides internal oversight infrastructure across every portfolio company — reviewing financials, monitoring budgets, tracking milestones, and keeping documentation structured and organised. Participating companies cover the cost through a flat fee once funds are committed, so family offices benefit from a dedicated oversight layer with no additional burden.

Flat fee model
Paid by portfolio companies — only after funds are committed
No upfront fee. No commission. Companies pay a flat fee to Steward only once their funding goal has been committed, covering all oversight services for the duration of the investment.

For family offices
Semi-annual internal financial review across all portfolio positions
Quarterly milestone progress check-ins per company
Financial documents organised and structured for internal review
Escrow managed by Steward's retained escrow attorney
No operational burden — Steward handles the oversight layer
For portfolio companies
Guaranteed funding pathway — funds released when goal is reached
No upfront fee and no commission to Steward
Flat fee to Steward begins only once funds are committed
Advisory access and structured internal oversight from funding close
Who We Work With

Built for three parties.
Designed to serve all of them.

Steward sits at the intersection of family office capital, early-stage innovation, and professional legal oversight. Each relationship is structured to be mutually reinforcing — and each party gets exactly what they need to move forward with confidence.

For investors
Family Offices
Steward gives family offices the confidence to invest directly in early-stage life sciences — with full internal oversight, structured reporting, and escrow protection built in from the start.
  • Direct investment — no fund manager or management fee
  • Semi-annual financial review and quarterly milestone check-ins
  • Escrow protection — capital returned if goal is not met
  • Curated deal flow — two filters before it reaches you
  • $50K–$250K per position — ~$2M deployed over ~2 years
Learn more →
The oversight entity
Steward Non-Profit
Steward is the active oversight layer at the center of every investment — not a passive administrator. Steward reviews financials, monitors operations, advises companies on gaps, manages escrow, and keeps all parties informed and accountable at every stage.
  • Non-profit structure — mission-aligned, not profit-driven
  • Expert deal sourcing, screening, and initial company review
  • Active financial supervision and budget monitoring
  • Operational oversight — advises on gaps and course corrections
  • Escrow managed through Steward's retained escrow attorney
  • Flat fee from portfolio companies — begins after funding is committed
About Steward →
For applicants
Life Sciences Companies
Early-stage companies gain access to a curated network of direct family office investors — alongside active oversight and advisory support that helps them stay on track and build investor confidence.
  • Apply directly or receive a proactive invitation
  • Filed IP ownership required to qualify
  • Funds released when full funding goal is reached
  • No upfront fee — flat fee begins only after commitment
  • Steward advises on operational gaps and milestone planning
Apply now →
The oversight ecosystem
Law Firm Partner
IP review · Scientific assessment · Deal terms
Partner opportunity
Open to qualified firms
Steward · Non-profit oversight entity
Full-spectrum oversight
Steward is the active oversight layer — not just an administrator. Every portfolio company receives hands-on financial supervision, operational guidance, and milestone accountability throughout the investment lifecycle.
Deal sourcingInitial screeningFinancial supervisionBudget oversightOperational advisoryMilestone trackingEscrow coordinationInvestor reportingGap identificationCourse correction
Escrow Attorney
Capital management · Secure release · Retained by Steward
Partner opportunity
Open to qualified firms
Non-profit
Mission-aligned oversight entity — not profit-driven
3-party
Family offices, portfolio companies, and legal partners
2 filters
Every deal passes Steward's expert review and the law firm's IP assessment
Semi-annual
Consolidated financial review plus quarterly milestone check-ins
Company Application

Apply to the
Steward programme.

Early-stage life sciences companies (biotech, healthcare, and medical device) can apply directly below. Applications are reviewed within 30–45 days. The minimum requirement to qualify is filed IP that you have control over.

Frequently Asked Questions

Everything you need
to know about Steward.

Questions answered for both audiences. Select your perspective below or browse all questions.

Still have questions?
Our team is happy to walk you through the Steward model in detail — whether you're a family office exploring direct investment or an early-stage company considering applying.
Get in touch →